# Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer

> **NIH NIH R44** · CONVERGENT GENOMICS, INC. · 2021 · $1,635,549

## Abstract

Bladder cancer is the 5th most prevalent cancer with over 700,000 people living with the
disease in the US. The disease has a particularly high patient burden as it recurs in 70% of
patients following initial treatment. Over half of these patients do not respond or progress while
on treatment or surveillance. New therapeutic and diagnostic options are needed for patients
undergoing diagnosis and recurrence surveillance.
 This project is supporting the continued technical and clinical development of UriSeq, a
diagnostic test for bladder cancer. This project will support development of expanded clinical
validity, clinical utility and health economics on over 3,000 longitudinally monitored bladder
cancer patients.

## Key facts

- **NIH application ID:** 10200688
- **Project number:** 5R44CA200174-05
- **Recipient organization:** CONVERGENT GENOMICS, INC.
- **Principal Investigator:** Trevor Levin
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,635,549
- **Award type:** 5
- **Project period:** 2016-09-01 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10200688

## Citation

> US National Institutes of Health, RePORTER application 10200688, Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer (5R44CA200174-05). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10200688. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*